secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062941
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Q3 net loss $9.3M; inks BioCryst licensing deal for DME with $5M upfront
--------------------------------------------------------------------------------

- Net loss of $9.3M ($0.15/share) vs $7.8M loss ($0.13/share) in Q3 2022.
- Cash $28.8M at Sep 30; +$5M upfront from BioCryst extends runway into Q4 2024.
- Licensed avoralstat (plasma kallikrein inhibitor) to BioCryst for DME; up to $77.5M milestones plus royalties.
- Completed recruitment in Phase 2b ODYSSEY wet AMD trial; topline data expected Q3 2024.
- Arctic Vision finished Phase 3 UME trial enrollment in China; Bausch+Lomb granted new CPT code for XIPERE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/0000950170-23-062941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/clsd-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer